" class="no-js "lang="en-US"> Jnana Therapeutics Cleared by FDA for Phenylketonuria Treatment
Friday, March 31, 2023

Breaking News

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria | PTF

January 6 2023

Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria

Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, has announced that it has received clearance from the US Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for the clinical study of JNT-517 for the treatment of phenylketonuria (PKU).

Jnana’s ongoing Phase 1 program of JNT-517 was initiated in Australia in the fourth quarter of 2022 in healthy volunteers (the Phase 1a sub-study). Following Phase 1a, the program will expand to include clinical sites in the U.S., and the Phase 1b sub-study will evaluate JNT-517 in individuals with PKU, with the potential to demonstrate clinical proof of concept supporting a subsequent registrational program.

“Clearance of our IND for JNT-517 by the FDA, Jnana’s first IND filing, marks an exciting next step for Jnana and we believe for individuals with PKU who have limited treatment options,” said Joanne Kotz, Ph.D., co-founder and CEO of Jnana Therapeutics. “We are very excited to advance our Phase 1 program and look forward to working with investigators, advocacy groups, and individuals living with PKU.”

Companies In This Post

FDA | Pharmtech Focus

FDA
  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)

    Clinical Trials

     Read more
More On